Myriad Genetics, Inc.  

(Public, NASDAQ:MYGN)   Watch this stock  
Find more results for MYGN
21.81
+0.24 (1.11%)
Real-time:   1:20PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 21.49 - 22.10
52 week 19.10 - 46.24
Open 21.49
Vol / Avg. 391,575.00/1.72M
Mkt cap 1.52B
P/E 12.79
Div/yield     -
EPS 1.71
Shares 69.13M
Beta 0.56
Inst. own 119%
Dec 2, 2016
Myriad Genetics Inc Annual Shareholders Meeting (Estimated) - 11:00AM EST - Add to calendar
Nov 1, 2016
Q1 2017 Myriad Genetics Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Sep 12, 2016
Myriad Genetics Inc at Morgan Stanley Global Healthcare Conference - Webcast
Aug 9, 2016
Q4 2016 Myriad Genetics Inc Earnings Call - Webcast
Aug 9, 2016
Q4 2016 Myriad Genetics Inc Earnings Release
Aug 3, 2016
Myriad Genetics Inc to Acquire Assurex Health Conference Call - Webcast
Jun 30, 2016
Myriad Genetics Inc Conference Call to discuss NOVA Study Results - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2016
Net profit margin 19.15% 16.62%
Operating margin 19.10% 22.13%
EBITD margin - 25.67%
Return on average assets 16.38% 15.22%
Return on average equity 18.86% 17.77%
Employees 2,206 -
CDP Score - -

Address

320 S Wakara Way
SALT LAKE CITY, UT 84108-1214
United States - Map
+1-801-5843600 (Phone)
+1-801-5843640 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Myriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to enable optimal treatment, or assess a patient's risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. Its molecular diagnostic tests include myRisk Hereditary Cancer, BRACAnalysis CDx and COLARIS.

Officers and directors

John T. Henderson M.D. Independent Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
Mark C. Capone President, Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Walter M. Gilbert Ph.D. Independent Vice Chairman of the Board
Age: 83
Bio & Compensation  - Reuters
R. Bryan Riggsbee CPA Chief Financial Officer, Treasurer
Age: 45
Bio & Compensation  - Reuters
Alexander Ford Corporate Executive
Age: 48
Bio & Compensation  - Reuters
Ralph L. McDade Ph.D. President of Myriad RBM, Inc
Age: 61
Bio & Compensation  - Reuters
Bernard F. Tobin President of Crescendo Bioscience, Inc
Age: 58
Bio & Compensation  - Reuters
Richard M. Marsh Esq. Executive Vice President, General Counsel, Secretary
Age: 57
Bio & Compensation  - Reuters
Gary A. King Executive Vice President - International Operations
Age: 59
Bio & Compensation  - Reuters
Jerry S. Lanchbury Ph.D. Chief Scientific Officer
Age: 56
Bio & Compensation  - Reuters